{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:41:48Z","timestamp":1793198508296,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jbo.2021.100375","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T02:28:43Z","timestamp":1623378523000},"page":"100375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations"],"prefix":"10.1016","volume":"29","author":[{"given":"J.E.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Confavreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Weilbaecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Rhoades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.I.","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"El Badri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ariaspinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"D'Oronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.A.","family":"Guise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Van Poznak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2021.100375_b0005","article-title":"Risk factors for mortality among patients with SARS-CoV-2 infection: A longitudinal observational study","author":"Almaghlouth","year":"2020","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.jbo.2021.100375_b0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jbo.2021.100375_b0015","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","article-title":"Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma","volume":"10","author":"Barwick","year":"2019","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jbo.2021.100375_b0020","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s12094-016-1590-1","article-title":"SEOM Clinical Guideline for bone metastases from solid tumours","volume":"18","author":"Gravalos","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"10.1016\/j.jbo.2021.100375_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101674","article-title":"Cancer Cell Colonisation in the Bone Microenvironment","volume":"17","author":"Kan","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"27","key":"10.1016\/j.jbo.2021.100375_b0030","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1016\/j.jbo.2021.100375_b0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00223-017-0353-5","article-title":"Bone-Targeted Therapies in Cancer-Induced Bone Disease","volume":"102","author":"Sousa","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.1016\/j.jbo.2021.100375_b0040","first-page":"2533","article-title":"Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency","volume":"28","author":"Yang","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2021.100375_b0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2021.100375_b0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jbo.2021.100375_b0055","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.jbo.2021.100375_b0060","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jbo.2021.100375_b0065","first-page":"925","article-title":"Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review","volume":"29","author":"Ng","year":"2021","journal-title":"Support Care Cancer"},{"issue":"35","key":"10.1016\/j.jbo.2021.100375_b0070","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1200\/JCO.2017.73.7437","article-title":"Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)","volume":"35","author":"Shapiro","year":"2017","journal-title":"J Clin Oncol"},{"issue":"18 Pt 1","key":"10.1016\/j.jbo.2021.100375_b0075","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1158\/1078-0432.CCR-07-0247","article-title":"Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid","volume":"13","author":"Brown","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jbo.2021.100375_b0080","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbo.2021.100375_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115570","article-title":"Bisphosphonates and breast cancer - From cautious palliation to saving lives","volume":"140","author":"Coleman","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2021.100375_b0090","article-title":"Management of bone and metabolic effects of androgen deprivation therapy","author":"Russell","year":"2018","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.jbo.2021.100375_b0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000505376","article-title":"Fractures due to Aromatase Inhibitor Therapy for Breast Cancer: A Real-World Analysis of FAERS Data in the Past 15 Years","volume":"43","author":"Song","year":"2020","journal-title":"Oncol Res Treat"},{"issue":"6","key":"10.1016\/j.jbo.2021.100375_b0100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MOU.0000000000000101","article-title":"Androgen-deprivation-associated bone disease","volume":"24","author":"Skolarus","year":"2014","journal-title":"Curr Opin Urol"},{"issue":"31","key":"10.1016\/j.jbo.2021.100375_b0105","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jbo.2021.100375_b0110","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss","volume":"25","author":"Brown","year":"2020","journal-title":"A consensus position statement from an expert group, J Bone Oncol"},{"key":"10.1016\/j.jbo.2021.100375_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00067-X","article-title":"Dramatic drop in new cancer drug trials during the COVID-19 pandemic","author":"Wilkinson","year":"2021","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.jbo.2021.100375_b0120","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J Clin Oncol."},{"issue":"18","key":"10.1016\/j.jbo.2021.100375_b0125","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jbo.2021.100375_b0130","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline","volume":"38","author":"Saylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbo.2021.100375_b0135","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JOP.17.00013","article-title":"Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary","volume":"14","author":"Anderson","year":"2018","journal-title":"J Oncol Practice"},{"key":"10.1016\/j.jbo.2021.100375_b0140","doi-asserted-by":"crossref","unstructured":"Coleman R, Hadji P, Body J-J, et al., Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 202; 31: 165-1663.","DOI":"10.1016\/j.annonc.2020.07.019"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137421000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137421000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:18:41Z","timestamp":1761941921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137421000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":28,"alternative-id":["S2212137421000300"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2021.100375","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2021.100375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100375"}}